What Does Naproxen Deplete? 3 Nutrients Affected

Naproxen is a non-selective cyclooxygenase inhibitor prescribed to approximately 10 million Americans annually via prescription brands Naprosyn and Anaprox, with substantial additional use as the over-the-counter product Aleve for pain, inflammation, and fever. According to ChEMBL mechanism-of-action data, naproxen inhibits both COX-1 (PTGS1) and COX-2 (PTGS2) enzymes, blocking the conversion of arachidonic acid to prostaglandins that mediate inflammation, pain signaling, and — critically — gastrointestinal mucosal protection. With oral bioavailability of 99%, peak plasma concentration at 2 hours, plasma protein binding of 99%, and an elimination half-life of 12-17 hours, naproxen achieves near-complete absorption and maintains pharmacologically active concentrations for most of a 24-hour period. This extended exposure window is the key pharmacological distinction from ibuprofen (half-life 2-4 hours) — while convenient for twice-daily dosing, it also means prolonged COX-1 suppression in the GI tract, producing more cumulative mucosal damage per day and proportionally greater nutrient malabsorption.

The Comparative Toxicogenomics Database catalogs 77 gene interactions for naproxen, with 2,838 total disease associations and 118 curated disease links — a substantial molecular footprint driven by the drug's broad cyclooxygenase inhibition across virtually every tissue type. Nutrient depletion through naproxen occurs primarily through the gastric mucosal damage pathway. COX-1-derived prostaglandins normally maintain a bicarbonate-mucus barrier that protects the stomach and duodenal lining from hydrochloric acid. When naproxen suppresses this protective layer, microscopic erosions and petechial bleeding develop in approximately 70% of chronic NSAID users, even at standard over-the-counter doses. This chronic blood loss depletes iron stores progressively. The mucosal damage simultaneously impairs the brush-border enzymes required for folate absorption in the jejunum, and the inflammatory tissue response increases systemic oxidative stress that consumes vitamin C reserves. Across 626 randomized controlled trials involving 537,499 patients in the naproxen knowledge graph, GI adverse events including bleeding, ulceration, and perforation are the most frequently documented complications, directly linking the therapeutic mechanism to the nutrient depletion pathway.

PharmGKB pharmacogenomic annotations for naproxen include variants in CYP2C9 and SULT1A1 that affect drug metabolism and efficacy, though without the high-level clinical guideline evidence assigned to some other NSAIDs. CYP2C9 poor metabolizers experience slower naproxen clearance and higher drug exposure, potentially amplifying both therapeutic effects and GI toxicity — and by extension, the severity of iron, folate, and vitamin C depletion. A notable clinical advantage of naproxen over other NSAIDs is its cardiovascular safety profile: across 4,422 PubMed-indexed articles, naproxen consistently demonstrates lower cardiovascular event risk than ibuprofen and diclofenac, making it the preferred NSAID for patients with cardiac risk factors. However, this cardiovascular benefit comes with the trade-off of greater GI bleeding risk per 24-hour period due to sustained COX-1 suppression, creating a clinical decision point where cardiovascular protection must be balanced against nutrient depletion from chronic mucosal damage. For patients requiring long-term NSAID therapy, pairing naproxen with a proton pump inhibitor reduces GI bleeding but introduces the PPI's own 6-nutrient depletion profile — a compounding effect that warrants comprehensive nutrient monitoring.